Related Experiment Video
Updated: Jan 16, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Premna puberula P. Ethyl Acetate Extract Treats Ulcerative Colitis by Regulating the Intestinal Flora and Improving
Zhichao Wang1, Yanmei Zhang2, Yun Huang2
1College of Biological and Food Engineering, Hubei Minzu University, Enshi 445000, China.
Abstract:
The prevalence of Ulcerative Colitis (UC) is continuously increasing globally, demanding the urgent search for new treatment agents due to the limitations of existing therapies. Premna puberula Pamp. (PP), a traditional medicinal and dietary plant, has anti-inflammatory properties. Its extracts' therapeutic benefits for UC have not been documented, though. Therefore, we aim to investigate the therapeutic effects of PPEAC on UC, providing a reference for new UC therapies. In our study, we used UPLC-MS/MS to determine the composition of Premna puberula Pamp's ethyl acetate extract (PPEAC). We assessed the effectiveness of PPEAC using a UC mouse model. The results demonstrated that PPEAC significantly reduced the Disease Activity Index (DAI) scores, lowered liver and spleen weight ratios, mitigated colonic shortening and histopathological damage, and alleviated oxidative stress. This research represented the first systematic investigation into the molecular mechanism of PPEAC ameliorating UC by modulating the intestinal flora-metabolism axis. PPEAC appeared to have a therapeutic impact on UC by boosting phosphatidylcholine (PC) analog levels and the number of Firmicutes and Muribaculaceae, as well as altering alpha-linolenic acid metabolism. Our research provided a new therapeutic approach for using PP as a traditional functional plant for food and medicine, as well as a new viewpoint for the creation of UC-targeted treatments based on conventional herbs.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

